The U.S. Food and Drug Administration (FDA) approved a supplemental efficacy application for Tecentriq (atezolizumab) on December 18, 2020. This approval, sponsored by Genentech Inc., indicates an expansion of the drug's approved uses based on new efficacy data.
Background
Atezolizumab, marketed as Tecentriq, is an established cancer immunotherapy. It is a monoclonal antibody that targets the PD-L1 protein, playing a crucial role in the immune system's ability to recognize and attack cancer cells. The drug has received multiple prior approvals for various cancer indications. Supplemental applications are filed by sponsors to expand the approved uses of an already marketed drug, often for new patient populations, disease stages, or treatment combinations, based on new clinical efficacy data.
What this means
This supplemental approval for Tecentriq (atezolizumab) signifies that the FDA has reviewed and accepted new efficacy data supporting an expanded use for the drug. While the specific new indication or patient population is not detailed in the provided information, such approvals typically allow clinicians to prescribe the drug for a broader range of patients or disease contexts where its efficacy has been demonstrated. This expands the therapeutic options available for patients who may benefit from atezolizumab, reflecting ongoing research and development in its clinical application.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on December 18, 2020. The approval details are available on the accessdata.fda.gov website, under application number BLA761034, for a supplemental application classified as efficacy.